Maxim Group Sticks to Their Buy Rating for Matinas BioPharma (MTNB)
August 12 2022 - 11:35AM
TipRanks
In a report released yesterday, Jason McCarthy from Maxim Group
maintained a Buy rating on Matinas BioPharma (MTNB - Research
Report), with a price target of $3.00. The company's shares opened
today at $0.85.According to TipRanks, McCarthy is an analyst with
an average return of -38.2% and a 14.81% success rate. McCarthy
covers the Healthcare sector, focusing on stocks such as Atossa
Therapeutics, Daré Bioscience, and Capricor Therapeutics.Currently,
the analyst consensus on Matinas BioPharma is a Strong Buy with an
average price target of $3.00, implying a 252.94% upside from
current levels. In a report released today, H.C. Wainwright also
reiterated a Buy rating on the stock with a $3.
https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-matinas-biopharma-mtnb?utm_source=advfn.com&utm_medium=referral
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jan 2023 to Feb 2023
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Feb 2022 to Feb 2023